Dr Reddy's Laboratories (Dr Reddy's Laboratories) COGS-to-Revenue

: 0.42 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Dr Reddy's Laboratories's Cost of Goods Sold for the three months ended in Dec. 2023 was $360 Mil. Its Revenue for the three months ended in Dec. 2023 was $867 Mil.

Dr Reddy's Laboratories's COGS to Revenue for the three months ended in Dec. 2023 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Dr Reddy's Laboratories's Gross Margin % for the three months ended in Dec. 2023 was 58.50%.

Dr Reddy's Laboratories COGS-to-Revenue Historical Data

The historical data trend for Dr Reddy's Laboratories's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

0.46

0.47

0.43

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue																0.41	0.43	0.41	0.41	0.42

Dr Reddy's Laboratories COGS-to-Revenue Calculation

Dr Reddy's Laboratories's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1295.011	/	2988.811
	=	0.43

Dr Reddy's Laboratories's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	359.682	/	866.601
	=	0.42

Dr Reddy's Laboratories (NYSE:RDY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Dr Reddy's Laboratories's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	359.682 / 866.601
	=	58.50 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Dr Reddy's Laboratories COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.